Compare Wockhardt with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WOCKHARDT vs VENUS REMEDIES - Comparison Results

WOCKHARDT     Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WOCKHARDT VENUS REMEDIES WOCKHARDT/
VENUS REMEDIES
 
P/E (TTM) x -22.2 -1.0 - View Chart
P/BV x 1.2 0.1 1,608.5% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 WOCKHARDT   VENUS REMEDIES
EQUITY SHARE DATA
    WOCKHARDT
Mar-18
VENUS REMEDIES
Mar-18
WOCKHARDT/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs1,012126 803.8%   
Low Rs53261 869.9%   
Sales per share (Unadj.) Rs355.9301.8 117.9%  
Earnings per share (Unadj.) Rs-60.3-24.9 242.4%  
Cash flow per share (Unadj.) Rs-46.82.5 -1,837.7%  
Dividends per share (Unadj.) Rs0.010-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs257.8293.3 87.9%  
Shares outstanding (eoy) m110.6312.34 896.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.20.3 700.0%   
Avg P/E ratio x-12.8-3.8 340.6%  
P/CF ratio (eoy) x-16.536.7 -44.9%  
Price / Book Value ratio x3.00.3 939.0%  
Dividend payout %00-   
Avg Mkt Cap Rs m85,3791,154 7,399.8%   
No. of employees `0006.30.9 676.1%   
Total wages/salary Rs m9,371393 2,383.8%   
Avg. sales/employee Rs Th6,295.04,026.1 156.4%   
Avg. wages/employee Rs Th1,498.3425.0 352.6%   
Avg. net profit/employee Rs Th-1,066.3-331.8 321.4%   
INCOME DATA
Net Sales Rs m39,3693,724 1,057.1%  
Other income Rs m1,20223 5,343.6%   
Total revenues Rs m40,5713,747 1,082.9%   
Gross profit Rs m18395 4.6%  
Depreciation Rs m1,495338 442.0%   
Interest Rs m2,555354 721.1%   
Profit before tax Rs m-2,830-275 1,027.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-3,5820-   
Tax Rs m25732 813.3%   
Profit after tax Rs m-6,669-307 2,172.9%  
Gross profit margin %010.6 0.4%  
Effective tax rate %-9.1-11.5 79.1%   
Net profit margin %-16.9-8.2 205.5%  
BALANCE SHEET DATA
Current assets Rs m33,7962,638 1,281.3%   
Current liabilities Rs m26,9172,305 1,167.9%   
Net working cap to sales %17.58.9 195.4%  
Current ratio x1.31.1 109.7%  
Inventory Days Days79135 58.6%  
Debtors Days Days8946 192.6%  
Net fixed assets Rs m39,6644,871 814.3%   
Share capital Rs m553123 448.3%   
"Free" reserves Rs m27,9683,496 800.1%   
Net worth Rs m28,5223,619 788.1%   
Long term debt Rs m21,7311,374 1,581.1%   
Total assets Rs m81,6207,509 1,087.0%  
Interest coverage x-0.10.2 -48.2%   
Debt to equity ratio x0.80.4 200.6%  
Sales to assets ratio x0.50.5 97.2%   
Return on assets %-5.00.6 -798.4%  
Return on equity %-23.4-8.5 275.7%  
Return on capital %-7.71.6 -485.1%  
Exports to sales %00-   
Imports to sales %013.9 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA517 0.0%   
Fx inflow Rs m9,8070-   
Fx outflow Rs m1,789517 346.3%   
Net fx Rs m8,019-517 -1,552.5%   
CASH FLOW
From Operations Rs m684514 133.0%  
From Investments Rs m6,302-123 -5,119.7%  
From Financial Activity Rs m-7,695-387 1,987.8%  
Net Cashflow Rs m-6644 -15,809.5%  

Share Holding

Indian Promoters % 74.5 32.9 226.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.3 0.2 1,277.8%  
FIIs % 7.7 0.6 1,327.6%  
ADR/GDR % 0.1 0.0 -  
Free float % 15.4 66.4 23.2%  
Shareholders   67,757 20,121 336.7%  
Pledged promoter(s) holding % 0.0 36.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WOCKHARDT With:   AJANTA PHARMA  FDC LTD.  SHASUN PHARMA  FRESENIUS KABI ONCO.  TTK HEALTHCARE  

Compare WOCKHARDT With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

WOCKHARDT Announces Quarterly Results (1QFY20); Net Profit Up 57.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, WOCKHARDT has posted a net profit of Rs 369 m (up 57.2% YoY). Sales on the other hand came in at Rs 9 bn (down 14.3% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

WOCKHARDT Announces Quarterly Results (4QFY19); Net Profit Up 90.8% (Quarterly Result Update)

May 7, 2019 | Updated on May 7, 2019

For the quarter ended March 2019, WOCKHARDT has posted a net profit of Rs 139 m (up 90.8% YoY). Sales on the other hand came in at Rs 10 bn (down 3.8% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

VENUS REMEDIES Announces Quarterly Results (3QFY19); Net Profit Down 2301.8% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, VENUS REMEDIES has posted a net profit of Rs 119 m (down 2301.8% YoY). Sales on the other hand came in at Rs 691 m (down 25.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

WOCKHARDT LTD. Announces Quarterly Results (3QFY19); Net Profit Down 80.6% (Quarterly Result Update)

Jan 29, 2019 | Updated on Jan 29, 2019

For the quarter ended December 2018, WOCKHARDT LTD. has posted a net profit of Rs 769 m (down 80.6% YoY). Sales on the other hand came in at Rs 10 bn (up 4.0% YoY). Read on for a complete analysis of WOCKHARDT LTD.'s quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

WOCKHARDT SHARE PRICE


Sep 20, 2019 (Close)

TRACK WOCKHARDT

  • Track your investment in WOCKHARDT with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

WOCKHARDT - SANOFI INDIA COMPARISON

COMPARE WOCKHARDT WITH

MARKET STATS